NCT02977468View on ClinicalTrials.gov

Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 25, 2017

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Merck 3475 Pembrolizumab

Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of one to two cycles.

RADIATION

Intraoperative radiation therapy (IORT)

Participants will receive Intraoperative radiation therapy (IORT) on the day of surgery.

Trial Locations (3)

10032

RECRUITING

Columbia University Irving Medical Center, New York

30322

RECRUITING

Emory University, Atlanta

60153

RECRUITING

Loyola University Chicago, Maywood

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Eileen Connolly

OTHER